NCT00216723
Completed
Not Applicable
Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder
DrugsAripiprazole
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Schizophrenia
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Enrollment
- 3000
- Locations
- 2
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder.
Detailed Description
This is a multicenter,open-label,prospective study of Aripiprazole use in patients with schizophrenia and bipolar disorder. Qualified schizophrenia patients will be enrolled to an 12-week treatment phase of Aripiprazole by physician's assessment. Qualified bipolar disorder patients will be enrolled to an 8-week treatment phase of Aripiprazole by physician's assessment. This study will be continued for 6 years. The final report of Aripiprazole PMS will be submitted to KFDA on December 28, 2009.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with a schizophrenia or schizoaffective disorder or bipolar disorder according to DSM-IV criteria
- •Age: more than 18 years of age
Exclusion Criteria
- •Unqualified patients judged by study investigator(s)
Outcomes
Primary Outcomes
Not specified
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 1
Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than AripiprazoleSchizophreniaNCT01552772Otsuka Pharmaceutical Development & Commercialization, Inc.60
Recruiting
Not Applicable
Real-life Assessment of Abilify Maintena + Rexult in SchizophreniaSchizophrenia and Related DisordersAnxiety DepressionNCT05169268The University of Hong Kong10
Completed
Phase 4
Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietySchizophreniaSchizoaffective DisorderSocial Anxiety DisorderNCT00177008University of Medicine and Dentistry of New Jersey18
Completed
Phase 4
Effect on Cognitive Function of a Treatment With AripiprazoleSchizophreniaNCT00329810Otsuka Pharmaceutical Development & Commercialization, Inc.500
Completed
Not Applicable
Aripiprazole research over schizophrenia patients (both on first episode and recurrence) about its efficacy and influence on cognitive functioschizophreniaJPRN-UMIN000002076Kyoto University Hospital20